Skip to main content

Table 1 Patient Characteristics (n = 15)

From: Phase I clinical trial of a novel autologous modified-DC vaccine in patients with resected NSCLC

Characteristics No. of Patients %
Sex
 Female 3 20
 Male 12 80
Age, years
 Median 50
 Range 40–61
ECOG PS
 0 15 100
Histologic subtypes
 Adenocarcinoma 10 66.7
 Squamous carcinoma 4 26.7
 Adenosquamous carcinoma 1 6.7
Tumor stage (AJCC)
 IA 4 26.7
 IB 6 40
 IIA 2 13.3
 IIB 1 6.7
 IIIA 2 13.3
Lymph node metastasis
 Yes 2 13.3
 No 13 86.67
History of chemotherapy
 Yes 12 80
 No 3 20
History of radiotherapy
 Yes 0 0
 No 15 100
  1. Abbreviations; ECOG Eastern Cooperative Oncology Group, PS Performance status